Lean PMOS: When You Have the Condition Without the Weight Changes

Key takeaways

• Polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) occurs across the whole body weight range. Body weight is not part of the diagnostic criteria.

• ”Lean PMOS” is an informal term used in the literature for the condition without excess body weight. It is not a separate diagnosis.

• Metabolic features can be present without excess weight.

• How much of the metabolic picture is intrinsic to the condition and how much relates to body weight is genuinely debated, and studies disagree.

• A normal BMI is not a reason to skip metabolic assessment. Current guidelines recommend assessing glycemic status at diagnosis in all adults and adolescents with PMOS, regardless of BMI, with repeat assessment based on individual risk factors.

PMOS occurs across the whole range of body weights, and body weight is not one of its diagnostic criteria. The informal term ”lean PMOS” refers to having the condition without excess body weight. Metabolic features can be present in this group, although how much of that is intrinsic to the condition rather than weight-related is still debated in the research.

Can you have PMOS at a normal weight?

Yes. Body weight is not among the diagnostic criteria.

Diagnosis in adults requires two of three features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone, after other causes are excluded (DOI: 10.1210/clinem/dgad463).1 Weight appears nowhere in that list.

The condition is more commonly identified in people with higher body weight, which is part of why the assumption persists.2 But being at a weight considered normal neither rules it out nor makes it a milder version of the same thing.

What does ”lean PMOS” actually mean?

It is an informal label, not a separate condition.

The term is used in the research literature to describe people who have the condition without excess body weight.2 There is no separate diagnostic pathway, no different criteria, and no distinct entry in any guideline. Someone described as having lean PMOS has PMOS.

The label is useful for one reason only: it names a group whose experience is frequently overlooked, both in clinics and in the material written for patients. It is not a subtype.

Are metabolic features present without excess weight?

Often, yes — and this is where the research becomes genuinely interesting rather than settled.

The 2023 International Evidence-Based Guideline strengthened recognition of the metabolic features associated with the condition, including metabolic risk factors and cardiovascular disease.1 Those associations are not framed as applying only above a particular weight.

Research in this area has looked specifically at people without excess adiposity. One population-based cohort study of adolescents found that those with the condition and a BMI below the 85th percentile had greater insulin resistance and an altered adipokine profile than those without it, with no difference in adiposity measures between the two groups (DOI: 10.1210/clinem/dgaf606).3 That points towards metabolic differences that are not explained by body fat.

Why the research disagrees

Other studies point the other way, and it would be misleading to present this as resolved.

Some work has found insulin resistance strongly tied to body weight, with a much higher proportion affected among those with higher BMI than among those at normal weight. Other work has found little difference between the two groups. The disagreement is real.

Part of the explanation is measurement. Insulin resistance is assessed by several different methods, with different thresholds, in populations recruited in different ways — often through fertility clinics, which selects a particular group. Studies using different methods can reach different conclusions about the same underlying question.

One framing used in the literature is a distinction between insulin resistance intrinsic to the condition itself and insulin resistance related to body weight, with the suggestion that people without excess weight may have the first while those with excess weight have both (DOI: 10.4103/jhrs.jhrs_77_17).4 It is a useful way to think about it. It is a proposed model, not a settled finding.

What this means practically: the honest answer is that metabolic features can be present without excess weight, that this is well enough established to matter clinically, and that the size and origin of the effect are still being worked out.

Why this matters for care

Because assumptions shape what gets assessed.

If metabolic features are treated as something that follows from body weight, then a person at a normal weight may not have them looked at. The guideline’s recognition of metabolic risk is not conditional on weight.1

Two things follow. A normal BMI is not a reason for metabolic health to go unassessed. And if you have been told your symptoms cannot be this condition because of your size, that reasoning does not match the diagnostic criteria, which do not mention weight at all.

What this means for tracking with Premom

Premom is an ovulation tracking application. It is not intended to diagnose, treat, cure, or prevent any disease, including PMOS. The information provided is for educational purposes and should not replace consultation with a healthcare provider.

Nothing in this article is visible in a tracking app. Androgen levels and metabolic health are assessed clinically and with appropriate laboratory testing, and cannot be inferred from cycle-tracking data.

What a record of cycle dates and test results across months contributes is one strand of a clinical picture — the ovulatory-dysfunction strand — in a form that is easier to bring to an appointment than to recall.

That is its whole role here.

Log your cycle dates in the Premom app

When to talk to a clinician

The information here is general and is not a basis for self-diagnosis or for changing anything about your health on your own. Speak with a clinician if:

• You have symptoms that fit and have been told your weight rules the condition out

• You have a diagnosis and metabolic health has never been discussed with you

• You want to understand what assessment, if any, is appropriate for you

• Your cycles are consistently long or vary widely from month to month

Frequently asked questions

About PMOS

Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by international consensus published in The Lancet on 12 May 2026.5 A three-year transition runs to 2028, and both names remain in clinical use. Diagnostic criteria did not change, and an existing PCOS diagnosis remains valid.

Reported prevalence varies with the criteria applied; the 2023 International Evidence-Based Guideline reports 10–13% (DOI: 10.1210/clinem/dgad463).1

References

1. Teede HJ, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI 10.1210/clinem/dgad463 · PMID 37580314.

2. Strauss JF III, Barbieri RL, eds. Yen & Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. 8th ed. Elsevier; 2019. ISBN 978-0-323-47912-7.

3. Adolescent ”lean PCOS” is characterized by higher insulin resistance and adverse adipokine profile. J Clin Endocrinol Metab. DOI 10.1210/clinem/dgaf606 · PMCID PMC12867335.

4. Debates regarding lean patients with polycystic ovary syndrome. J Hum Reprod Sci. DOI 10.4103/jhrs.jhrs_77_17.

5. Teede HJ, et al. The Lancet, 12 May 2026. DOI 10.1016/S0140-6736(26)00717-8 · PMID 42119588.

Read nextDoes Acupuncture Help with PCOS Ovulation?→